MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
*Portfolio Companies: Healthcare Ventures
Theraclone Sciences, Inc (Formerly, Spaltudaq)
Attachments
Medical Information & Trusted Health Advice
Parents
*Industry: Seattle
*Industry: Washington
*Portfolio Companies: Amgen
*Portfolio Companies: Arch Ventures
*Portfolio Companies: Healthcare Ventures
*Portfolio Companies: Versant
Architects: Biotechnology _Monoclonal, Polyclonal, Bispecific Antibodies & Antibody-Drug Conjugates (ADC)s
Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology
Architects: Infectious Disease _ HIV/AIDS & STDs
Children
*Portfolio Companies: Accelerator Corporation
2011: Consortium Find New HIV Antibodies, Zogenix Gets Drug to Clinical End Point, TrovaGene Reclaims Technology, & More San Diego Life Sciences News (2011)
2011: Series B $10.6M by OnBioVC (2011)
2011: Theraclone Sciences Inc Snaps Up $10.6 Million Series B Financing (2011)
Allows multiple candidate antibodies to be evaluated in a short period of time
Company portfolio's technology platform, In Situ Tumor-Specific Antibody Rescue (I-STAR),
Developing novel tumor-specific therapeutic antibodies for the treatment of cancer
Founded 2005
Harnesses the specificity of the immune system to isolate tumor-specific antibodies
Leads to the identification and testing of fully human antibodies within ten to fourteen days of the initial sample analysis
Seattle, Washington
Spaltudaq graduated from Accelerator with some $29 million in March 2007.
Spaltudaq's process is very rapid,
The company’s I-STAR™ technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects.
Theraclone Sciences is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation.
Theraclone Sciences, Inc. and Pfizer Inc. Enter into Infectious Disease and Cancer Antibody Discovery Collaboration; Pfizer(2011)
Tumor-specific cancer antibody-based therapeutics
Venture investors include ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
Jumps
Amgen Inc. (NASDAQ:AMGN)
Pfizer Inc. (NYSE: PFE)